| Name | Title | Contact Details |
|---|---|---|
Dan Preston |
Chief Technology Officer | Profile |
Shanghai Lian Shang Network Technology Co., Ltd. is a focus on providing free Internet access and mobile Internet content and services companies, independent research and development of core products "WiFi Wan Can key "released in 2012, so far, WiFi master key of nearly 600 million total subscribers. WiFi master key is a WiFi network connection management software that helps users to automatically query the surrounding open free public Wi-Fi hot spot information and help users Easy to establish a connection, while providing WiFi power saving features, view the phone traffic consumption, quickly switch the phone to WiFi hotspots, as well as real-time test current network Speed and other functions. WiFi Skeleton Key is committed to providing users with the best WiFi management tools to help users maximize the use of various networking mobile services. All Hot Cloud-based database information, anytime, anywhere easy access to the wireless network, maximize the use of various networking mobile services, eliminate non-mesh net off state, especially for business, Mobile populations and severe worms.
Chestnut Associates is a Newark, CA-based company in the Software and Internet sector.
Adrian McGilly. is a Oakland, CA-based company in the Software and Internet sector.
Insight Quest Inc is a Chandler, AZ-based company in the Software and Internet sector.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.